Nasdaq

Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...
Seeking Alpha

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...
Nasdaq

Angle PLC Announces Launch of PD-L1 Test to Support Cancer Studies

GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...
Business Wire

LabCorp to Offer New PD-L1 Test for Bristol-Myers Squibb’s OPDIVO ® Following Collaboration in Clinical Trial

BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) today announced the nationwide availability of a new FDA-approved diagnostic test for PD-L1 ...
The American Journal of Managed Care

Serial CT Response Score Predicts OS in Patients With Advanced NSCLC Receiving ICIs

Serial CT response score (CTRS) predicted overall survival (OS) more effectively than existing imaging-based measures in patients with advanced non–small cell lung cancer (NSCLC) receiving immune ...